Clinical study on acute kidney injury after myeloablative allogeneic hematopoietic cell transplantation.
- Author:
Yu-shi BAO
1
;
Er-lie JIANG
;
Mei WANG
;
Yong HUANG
;
Jia-lin WEI
;
Dong-lin YANG
;
Si-zhou FENG
;
Ming-zhe HAN
Author Information
- Publication Type:Journal Article
- MeSH: Acute Kidney Injury; etiology; prevention & control; Adolescent; Adult; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Postoperative Complications; prevention & control; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Young Adult
- From: Chinese Journal of Hematology 2008;29(6):401-404
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the incidence, pathogenesis, risk factors, prophylaxis and treatment of acute kidney injury (AKI) after myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODSClinical data of 120 patients received myeloablative allo-HSCT were retrospectively analyzed.
RESULTSSerum creatinine level in the patients showed significantly higher than baseline value at 28-60 days after transplantation (P<0.05). 73 patients (60.8%) developed AKI at a median of 33 days after allo-HSCT, including grade 2 in 32 patients (26.7%). Patients with grade 1 AKI showed significant higher serum cyclosporine A (CsA) levels (P<0.05). Hepatic veno-occlusive disease( HVOD), acute graft-versus-host disease (aGVHD) and total bilirubin > 40 micromol/L were high risk factors of occurring AKI (P<0.05). 19 patients died within 100 days after allo-HSCT, grade 2 AKI was a high risk factor of mortality (P< 0.05). 180-day survival rate was significantly lower in patients with grade 2 AKI after allo-HSCT (P<0.05).
CONCLUSIONAKI is one of the major complications after myeloablative allo-HSCT. Prophylaxis and treatment of AKI might reduce mortality in early stage of transplantation.
